pharma · Steroid refractory Acute Graft versus host Disease · moderate to severe atopic dermatitis
Medac Gesellschaft fuer
Medac Gesellschaft fuer klinische Spezialpraeparate mbH
Medac Gesellschaft fuer is a pharma organization headquartered in EU. Primary therapeutic focus areas include Steroid refractory Acute Graft versus host Disease, moderate to severe atopic dermatitis. NovaPharmaNews links
EU HQ
EMA registrant Type
Company details
- Status
- Public
- HQ
- EU
- Programs
- 3
- Drugs
- 14
- Patents
- 0
MC-MTX.18/AD
Phase 3 · small molecule · moderate to severe atopic dermatitis
MC-MTX.18/AD for moderate to severe atopic dermatitis is a Phase 3 program (small_molecule) at Medac Gesellschaft fuer klinische Spezialpraeparate mbH with 1 ClinicalTrials.gov record(s).
Internal code MC-MTX.18/AD
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Medac Gesellschaft fuer klinische Spezialpraeparate mbH
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- moderate to severe atopic dermatitis
- Status
- active
- Trials
- 1